Applied DNA Sciences Inc (APDN) Given Consensus Rating of “Hold” by Analysts

Applied DNA Sciences Inc (NASDAQ:APDN) has been given a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating. Applied DNA Sciences’ rating score has declined by 200% from three months ago as a result of a number of analysts’ upgrades and downgrades.

Zacks has also assigned Applied DNA Sciences an industry rank of 197 out of 255 based on the ratings given to related companies.

Separately, Maxim Group lowered Applied DNA Sciences from a “buy” rating to a “hold” rating in a research note on Monday, December 31st.

In related news, major shareholder William W. Montgomery acquired 154,000 shares of Applied DNA Sciences stock in a transaction on Thursday, January 3rd. The stock was acquired at an average price of $0.44 per share, for a total transaction of $67,760.00. Following the purchase, the insider now owns 4,560,900 shares of the company’s stock, valued at approximately $2,006,796. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder William W. Montgomery acquired 400,000 shares of Applied DNA Sciences stock in a transaction on Monday, January 7th. The shares were bought at an average price of $0.45 per share, with a total value of $180,000.00. Following the purchase, the insider now directly owns 4,560,900 shares in the company, valued at approximately $2,052,405. The disclosure for this purchase can be found here. Insiders have acquired a total of 794,000 shares of company stock valued at $352,760 in the last quarter. Company insiders own 21.41% of the company’s stock.

A hedge fund recently raised its stake in Applied DNA Sciences stock. Chase Investment Counsel Corp lifted its holdings in Applied DNA Sciences Inc (NASDAQ:APDN) by 69.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,163 shares of the technology company’s stock after purchasing an additional 53,600 shares during the period. Chase Investment Counsel Corp owned about 0.44% of Applied DNA Sciences worth $195,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.11% of the company’s stock.

APDN traded up $0.18 on Tuesday, reaching $0.62. 21,204 shares of the stock were exchanged, compared to its average volume of 774,707. Applied DNA Sciences has a fifty-two week low of $0.30 and a fifty-two week high of $1.84. The company has a quick ratio of 1.60, a current ratio of 1.68 and a debt-to-equity ratio of 2.82.

Applied DNA Sciences (NASDAQ:APDN) last issued its quarterly earnings results on Thursday, February 7th. The technology company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.03). The firm had revenue of $0.88 million for the quarter. Applied DNA Sciences had a negative return on equity of 458.79% and a negative net margin of 283.98%.

About Applied DNA Sciences

Applied DNA Sciences, Inc develops and markets plat based or other DNA technology solution in the United States, Europe, and Asia. The company's supply chain security and product authentication solutions include SigNature molecular tags that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T molecular tags, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber DNA.

Featured Story: Understanding Analyst Recommendations

Get a free copy of the Zacks research report on Applied DNA Sciences (APDN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with's FREE daily email newsletter.

Leave a Reply